Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors

J. Strosberg*, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P. L. Kunz, M. H. Kulke, H. Jacene, D. Bushnell, T. M. O'Dorisio, R. P. Baum, H. R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, A. BensonR. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J. L. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1354 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences